Oppenheimer maintains Immunovant stock rating on next-gen drug focus.
Share this article
Corporate
Score 25
Neutral
Oppenheimer maintains Immunovant stock rating on next-gen drug focus
Apr 02, 2026 15:07 UTC
IMMV
Short term
Related Articles
Score 25
Form DEF 14A Weyco Group For: 2 April
Apr 02, 17:57
Score 25
Amazon Introduces 3.5% Fuel Surcharge for Third-Party Sellers
Apr 02, 17:53
Score 25
Horizon Kinetics buys Texas Pacific Land (TPL) share for $454
Apr 02, 17:52
Score 25
Bearish
TTM Technologies director Edman sells $1.68 million in stock
Apr 02, 17:43
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.